Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Psychiatric Quarterly
Erschienen in: Psychiatric Quarterly 4/2011

01.12.2011 | Original Paper

Social Interaction and Drug Attitude Effectiveness in Patients with Schizophrenia

verfasst von: Jui-Kang Tsai, Wen-Kuo Lin, For-Wey Lung

Erschienen in: Psychiatric Quarterly | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

This study aimed to explore the relationship between dosage of paliperidone and drug attitude, and also clarify the factors associated with drug attitude, using Intention-to-Treat (ITT) analysis. Three hundred thirty-one patients diagnosed with schizophrenia, who prescribed paliperidone between April 2008 and April 2009, from 10 hospitals in Taiwan were enrolled. By structural equation modeling, inpatient/outpatient status associated with occupation status, sex, and score on the Clinical Global Impression-Severity (CGIS) Scale. The score on the Personal and Social Performance (PSP) Scale associated with occupation status, inpatient/outpatient status, and the score on the CGIS Scale. The scores on the DAI-10 associated with the score on the PSP Scale and age. Good drug attitude and medication adherence significantly related to good social interaction. We should enhance the drug attitude and medication adherence of patients with schizophrenia who have poor social interaction to improve the outcome of schizophrenia.
Literatur
1.
Lesser IM, Friedmann CT: Attitudes toward medication change among chronically impaired psychiatric patients. American Journal of Psychiatry 138(6):801–803, 1981PubMed
2.
Rossi A, Pacifico R, Stratta P: Attitudes toward medication and the clinical variables in schizophrenia: Structural equation models. Patient Preference and Adherence 3:305–309, 2009PubMedCrossRef
3.
Naber D, Karow A: Good tolerability equals good results: The patient’s perspective. European Neuropsychopharmacology 11(4):S391–S396, 2001PubMedCrossRef
4.
Fenton WS, Blyler CR, Heinssen RK: Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophrenia Bulletin 23:637–651, 1998
5.
Garavan J, Browne S, Gervin M, et al.: Compliance with neuroleptic medication in outpatients with schizophrenia: Relationship to subjective response to neuroleptics; attitudes to medication and insight. Comprehensive Psychiatry 39:215–219, 1998PubMedCrossRef
6.
Marder SR: Facilitating compliance with antipsychotic medication. Journal of Clinical Psychiatry 59(3):21–25, 1998PubMed
7.
Lacro JP, Dunn LB, Dolder CR, et al.: Prevalence of end risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. Journal of Clinical Psychiatry 63:892–909, 2002PubMedCrossRef
8.
Misdrahi D, Llorca PM, Lancon C, et al.: Compliance in schizophrenia: Predictive factors, therapeutical considerations and research implications. L’Encephale 28:266–272, 2002PubMed
9.
Adewuya AO, Ola BA, Mosaku SK, et al.: Attitude towards antipsychotics among out-patients with schizophrenia in Nigeria. Acta Psychiatrica Scandinavica 113:207–211, 2006PubMedCrossRef
10.
Cabeza IG, Diaz SEI, Amador MS, et al.: Factors related to treatment adherence in schizophrenic patients. Actas Espanolas de Psiquiatria 27:211–216, 1999
11.
Adams SG, Howe JT: Predicting medication compliance in a psychotic population. The Journal of Nervous and Mental Disease 181:558–560, 1993PubMedCrossRef
12.
Naber D, Karow A, Lambert M: Subjective well-being under neuroleptics treatment and its relevance to compliance. Acta Psychiatrica Scandinavica 111:232–243, 2005PubMedCrossRef
13.
Buchanan A: A two year prospective study of treatment compliance in patients with schizophrenia. Psychological Medicine 22:787–797, 1992PubMedCrossRef
14.
Weiden P, Papkin B, Mott T, et al.: Rating of medication influences (ROMI) scale in schizophrenia. Schizophrenia Bulletin 20:297–310, 1994PubMed
15.
Dunn G, Maracy M, Dowrick C, et al.: Estimating psychological treatment effects from a randomised controlled trial with both non-compliance and loss to follow-up. British Journal of Psychiatry 183:323–331, 2003PubMedCrossRef
16.
Hollis S, Campbell F: What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 319(7211):670–674, 1999PubMedCrossRef
17.
Marino J, Caballero J: Paliperidone extended-release for the treatment of schizophrenia. Pharmacotherapy 28(10):1283–1298, 2008PubMedCrossRef
18.
Hogan TP, Awad AG, Eastwood R: A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity. Psychological Medicine 13(1):177–183, 1983PubMedCrossRef
19.
Townsend L, Floersch J, Findling RL: Adolescent attitudes toward psychiatric medication: The utility of the Drug Attitude Inventory. Journal of Child Psychology and Psychiatry 50(12):1523–1531, 2009PubMedCrossRef
20.
Cheng HL, Yu YW: Validation of the Chinese version of “the Drug Attitude Inventory”. Kaohsiung Journal of Medical Sciences 13:370–377, 1997PubMed
21.
Awad AG: Subjective response to neuroleptics in schizophrenia. Schizophrenia Bulletin 19(3):609–618, 1993PubMed
22.
Little R, Yau L: Intent-to-treat analysis for longitudinal studies with drop-outs. Biometrics 52(4):1324–1333, 1996PubMedCrossRef
23.
Kuroda N, Sun S, Lin CK, et al.: Attitudes toward taking medication among outpatients with schizophrenia: Cross-national comparison between Tokyo and Beijing. Environmental Health and Preventive Medicine 13(5):288–295, 2008PubMedCrossRef
24.
Hofer A, Rettenbacher MA, Edlinger M, et al.: Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: A prospective follow-up study in patients with schizophrenia. Acta Psychiatrica Scandinavica 116:354–361, 2007PubMedCrossRef
25.
Hofer A, Kemmler G, Eder U, et al.: Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. Journal of Clinical Psychiatry 63:49–53, 2002PubMedCrossRef
26.
Mohamed S, Rosenheck R, McEvoy J, et al.: Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophrenia Bulletin 35(2):336–346, 2009PubMedCrossRef
27.
Day JC, Bentall RP, Roberts C, et al.: Attitudes toward antipsychotic medication. The impact of clinical variables and relationships with health professionals. Archives of General Psychiatry 62:717–724, 2005PubMedCrossRef
28.
Marder SR, Mebane A, Chien CP, et al.: A comparison of patients who refused and consent to neuroleptics treatment. American Journal of Psychiatry 140:470–472, 1983PubMed
29.
Schennach-Wolff R, Jager M, Seemuller F, et al.: Attitude towards adherence in patients with schizophrenia at discharge. Journal of Psychiatric Research 43(16):1294–1301, 2009PubMedCrossRef
30.
Freudenreich O, Cather C, Evins AE, et al.: Attitudes of schizophrenia outpatients toward psychiatric medications: Relationship to clinical variables and insight. Journal of Clinical Psychiatry 65(10):1372–1376, 2004PubMedCrossRef
31.
Gaebel W, Pietzcker A: One year outcome of schizophrenic patients: The interaction of chronicity and neuroleptics treatment. Pharmacopsychiatry 18:235–239, 1985PubMedCrossRef
32.
Rocca P, Crivelli B, Marino F, et al.: Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia. Comprehensive Psychiatry 49(2):170–176, 2008PubMedCrossRef
33.
Patel MX, De Zoysa N, Bernadt M, et al.: Depot and oral antipsychotics: Patient preferences and attitudes are not the same thing. Journal of Psychopharmacology 23(7):789–796, 2009PubMedCrossRef
Metadaten
Titel
Social Interaction and Drug Attitude Effectiveness in Patients with Schizophrenia
verfasst von
Jui-Kang Tsai
Wen-Kuo Lin
For-Wey Lung
Publikationsdatum
01.12.2011
Verlag
Springer US
Erschienen in
Psychiatric Quarterly / Ausgabe 4/2011
Print ISSN: 0033-2720
Elektronische ISSN: 1573-6709
DOI
https://doi.org/10.1007/s11126-011-9177-z

Weitere Artikel der Ausgabe 4/2011

Psychiatric Quarterly 4/2011 Zur Ausgabe

Original Paper

Implications of Antisocial Parents

Original Paper

Factors Associated with Mental Health Utilization Among Minorities Following the Second Lebanon War in Israel

Original Paper

Religion and Mental Health During Incarceration: A Systematic Literature Review

Original Paper

Improvement in Global Psychopathology Increases Quality of Life During Treatment of ADHD with Atomoxetine or Stimulants

Original Paper

The Association Between Somatic Symptoms, Anxiety Disorders and Substance Use. A Literature Review

Original Paper

A Day in the Life of a Public Psychiatry Fellow

Neu im Fachgebiet Psychiatrie

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Spezielles Sportprogramm bei einer Reihe von psychischen Erkrankungen effektiv

08.05.2024 Psychotherapie Nachrichten

Sportliche Betätigung hilft nicht nur bei Depression, sondern auch in Gruppen von Patientinnen und Patienten mit unterschiedlichen psychischen Erkrankungen, wie Insomnie, Panikattacken, Agoraphobie und posttraumatischem Belastungssyndrom. Sie alle profitieren längerfristig.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise